Raynaud's phenomenon induced by drugs acting on neurotransmission: two cases under reboxetine and one under tegaserod.
Bertoli
Raffaela
R
Regional Pharmacovigilance Center Tessin, Lugano Regional Hospital, Via Tesserete 46, 6900, Lugano, Switzerland.
Girardin
François
F
Russmann
Stefan
S
Lauterburg
Bernhard H
BH
D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D009025:Morpholines / Q000009:adverse effects* / Q000627:therapeutic use; D011928:Raynaud Disease / Q000139:chemically induced*; D000077593:Reboxetine; D017366:Serotonin Receptor Agonists / Q000009:adverse effects* / Q000627:therapeutic use
D018759:Adrenergic Uptake Inhibitors; D007211:Indoles; D009025:Morpholines; D017366:Serotonin Receptor Agonists; C105050:tegaserod; D000077593:Reboxetine